These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 338927)
1. Mutagenic activity of major mammalian metabolites of cyclophosphamide toward several genes of Escherichia coli. Ellenbergen J J Toxicol Environ Health; 1977 Nov; 3(4):637-50. PubMed ID: 338927 [TBL] [Abstract][Full Text] [Related]
2. Mutagenic activity of cyclophosphamide, ifosfamide, and trofosfamide in different genes of escherichia coli and salmonella typhimurium after biotransformation through extracts of rodent liver. Ellenberger J; Mohn G Arch Toxicol; 1975; 33(3):225-40. PubMed ID: 1096853 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein. Hales BF Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914 [No Abstract] [Full Text] [Related]
4. Relative mutagenicity of some urinary metabolites of the antitumor drug cyclophosphamide. Balbinder E; Reich CI; Shugarts D; Keogh J; Fibiger R; Jones T; Banks A Cancer Res; 1981 Jul; 41(7):2967-72. PubMed ID: 7018675 [TBL] [Abstract][Full Text] [Related]
5. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Low JE; Borch RF; Sladek NE Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide. Gilbert DN; Starr P; Eubanks N Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269 [TBL] [Abstract][Full Text] [Related]
7. Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cai Y; Wu MH; Ludeman SM; Grdina DJ; Dolan ME Cancer Res; 1999 Jul; 59(13):3059-63. PubMed ID: 10397244 [TBL] [Abstract][Full Text] [Related]
8. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Struck RF; Kirk MC; Witt MH; Laster WR Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393 [TBL] [Abstract][Full Text] [Related]
9. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089 [TBL] [Abstract][Full Text] [Related]
10. Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives. Nau H; Spielmann H; Lo Turco Mortler CM; Winckler K; Riedel L; Obe G Mutat Res; 1982 Aug; 95(2-3):105-18. PubMed ID: 6750378 [TBL] [Abstract][Full Text] [Related]
11. Genotoxicity of 1,3-butadiene and its epoxy intermediates. Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF; Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413 [TBL] [Abstract][Full Text] [Related]
12. A demonstration of the in vitro bacterial mutagenicity of procarbazine, using the microtitre fluctuation test and large concentrations of S9 fraction. Gatehouse DG; Paes DJ Carcinogenesis; 1983; 4(3):347-52. PubMed ID: 6339100 [TBL] [Abstract][Full Text] [Related]
13. Relative mutagenicity and teratogenicity of cyclophosphamide and two of its structural analogs. Hales BF Biochem Pharmacol; 1983 Dec; 32(24):3791-5. PubMed ID: 6362674 [TBL] [Abstract][Full Text] [Related]
14. Studies on the metabolic activation of diethanolnitrosamine in animal-mediated and in vitro assays using Escherichia coli K-12 343/113 as an indicator. Knasmüller S; Stehlik G; Mohn G J Cancer Res Clin Oncol; 1986; 112(3):266-71. PubMed ID: 3536944 [TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Sladek NE; Doeden D; Powers JF; Krivit W Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Escherichia coli K-12 343/113 and derived strains for microbial mutagenicity assays. Leonardo JM; Dornfeld SS; Peak MJ Mutat Res; 1984 Apr; 130(2):87-95. PubMed ID: 6425682 [TBL] [Abstract][Full Text] [Related]
17. Role of the 4-hydroxy intermediate in the in vitro embryotoxicity of cyclophosphamide and dechlorocyclophosphamide. Slott VL; Hales BF Toxicol Appl Pharmacol; 1988 Feb; 92(2):170-8. PubMed ID: 3341031 [TBL] [Abstract][Full Text] [Related]
18. Toxicity, interstrand cross-links and DNA fragmentation induced by 'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard. Fleer R; Brendel M Chem Biol Interact; 1982 Mar; 39(1):1-15. PubMed ID: 7037214 [TBL] [Abstract][Full Text] [Related]
19. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629 [TBL] [Abstract][Full Text] [Related]
20. Mutagenic activity of three isomeric N-nitroso-N-methylaminopyridines towards Escherichia coli K-12 in in vitro and animal-mediated assays. Kerklaan P; Bouter S; Mohn G Carcinogenesis; 1982; 3(4):415-21. PubMed ID: 7046976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]